Dipeptidyl peptidase 4 (DPP-4) inhibitors and their role in Type 2 diabetes management
Dipeptidyl peptidase 4 (DPP-4) inhibitors are a new pharmacological class of drugs for treating Type 2 diabetes. They improve the capacity of the organism to control glycemia by increasing the levels of active incretins. Their mechanism of action is thus radically different from those of other anti-diabetic drugs currently available. DDP-4 inhibitors use a physiological mechanism to control hyperglycemia, by stimulating the secretion of insulin from β-cells, decreasing the secretion of glucagon from pancreatic α-cells, and at the same time reducing the production of glucose by the liver. DDP-4 inhibitors have shown significant efficacy in maintaining reduced levels of glycosylated hemoglobin for up to 1 year. In vitro and animal studies have shown that they can inhibit apoptosis of β-cells and favor their regeneration and differentiation. The oral DPP-4 inhibitors vildagliptin, sitagliptin, and saxagliptin are efficacious both alone and in association with other oral anti-diabetic agents and may be administered in a single daily dose. Lastly, they have substantial advantages with respect to other anti-diabetic drugs, since they involve a low risk of hypoglycemia and do not affect body weight.
Key-wordsIncretins insulin secretion Type 2 diabetes
Unable to display preview. Download preview PDF.
- 10.Rolin B. The novel xanthine-based DPPIV inhibitor NN7201 and LAF237 improve glucose tolerance, but do not prevent progression of diabetes in Zucker diabetic fatty rats. Diabetes 2004, 53 (Suppl 2): A341.Google Scholar
- 11.Mika A. Acute DPP IV inhibition minimizes glucose and insulin responses to a glucose challenge in a diabetic mouse. Diabetes 2003, 52 (Suppl 1): A350.Google Scholar
- 14.Dardik B. NVP-LAF237, a dipeptidyl peptidase IV inhibitor, improves glucose tolerance and delays gastric emptying in obese insulin resistant Cynomolgus monkeys. Diabetes 2003, 52 (Suppl 1): A322Google Scholar
- 15.Duttaroy A, Voelker F, Zhang X, et al. The DPP-4 inhibitor vildagliptin increases β cell mass in rodents. Diabetologia 2005, 48 (Suppl 1): A178.Google Scholar
- 18.Ahren B. Gomis R, Standl E, Mills D, Schweizer A. Twelve-and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004, 27: 2874–80.Google Scholar
- 19.Garber A, Camisasca R, Ersham E, et al. Vildagliptin added to metformin improves glycemic control and may mitigate metformin-induced GI side effects in patients with type 2 diabetes (T2DM). Diabetes 2006, 55 (Suppl 1): A29 (abstract 121-OR).Google Scholar
- 20.Nathwani A. The use of Vildagliptin for treatment of patients with type 2 diabetes. Late breaking clinical study presented at: 66th Annual Scientific Session of the American Diabetes Association, San Diego, CA, 2005 (http://www.diabetesconnect.org/cgi-bin/store/webcasts_speaker).
- 21.Dejager S, Lebeaut A, Couturier A, Schweizer A. Sustained reduction in HbA1c during one-year treatment with vildagliptin in patients with type 2 diabetes (T2DM). Diabetes 2006, 55 (Suppl 1): A29 (abstract 120-OR).Google Scholar
- 22.Fonseca V, Dejager S, Albrecht D, Shirt L, Schweizer A. Vildagliptin as add-on to insulin in patients with type 2 diabetes (T2DM). Diabetes 2006, 55 (Suppl 1): A111 (abstract 467-P).Google Scholar